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were signiﬁcantly lower compared to human insulin only patients
($20,709, p < 0.001) and those receiving both analog and human
insulins ($28,679, p < 0.001). Inpatient visits, length of stay,
emergency visits, and clinic visits were also signiﬁcantly lower
(p < 0.001) for analog-only patients. Hypoglycemia-related costs
and utilization and overall diabetes-related utilization followed
the same patterns. CONCLUSION: Patients receiving only
analog insulin had higher insulin costs but lower post-index total
health care costs and utilization, whether all-cause or diabetes-
related, compared to patients receiving human insulin or a com-
bination of analog and human insulins.
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OBJECTIVE: Anemia is a well known complication associated
with CKD. However, there are little data regarding its association
with hospitalizations. The purpose of this study was to investi-
gate whether anemia is associated with increased hospitalization
costs in patients with diabetes and chronic kidney disease (CKD).
METHODS: An analysis of medical claims and laboratory data
between January 2000 and February 2006 from over 45 health
plans contributing to the Ingenix Impact National Managed Care
Database was conducted. Inclusion criteria were 2 hemoglobin
(Hb) values, 2 claims (within a 90-day period) for diabetes
mellitus preceding 1 claim for CKD and 2 glomerular ﬁltra-
tion rate values of <60 mL/min/1.73 m2, and not yet on dialysis.
Patients were excluded if they had cancer or lupus, received
organ transplantation or chemotherapy, or were treated for
anemia with an erythropoiesis-stimulating agent or blood trans-
fusions. An open-cohort design was used to classify patients
into observation periods of anemia (Hb < 11 g/dL), within the
K/DOQI treatment recommendations, and non-anemia, which
allowed for changes in anemia status over time. Both univariate
and multivariate analyses were conducted to compare periods of
anemia and non-anemia for average yearly hospitalization costs.
RESULTS: A total of 708 patients with diabetes and CKD
formed the study population. Mean age was 65 years; 44%
women. Anemia was associated with a signiﬁcant increase in
hospitalization costs, with an unadjusted incremental yearly cost
of $17,072 (anemia: $25,342; non-anemia: $8270; p < .001)
relative to non-anemia. The majority of hospitalizations (57%)
were related to cardiovascular disease, with anemia increasing
the cost of cardiovascular-hospitalizations by $8647 (anemia:
$13,723; non-anemia: $5076; p < .001). After controlling for
covariates, anemia remained signiﬁcantly associated with a hos-
pitalization cost increase. CONCLUSION: The current study
based on real-life practice data demonstrated that anemia in
patients with diabetes and CKD was associated with a signiﬁcant
increase in hospitalization costs.
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OBJECTIVE: To measure the effects of a pharmacist-run medi-
cation management program on medication adherence, glycemic
control, and total health care expenditures. METHODS: Scott
& White Health Plan (SWHP) claims data were evaluated to
identify high-risk diabetics aged 18–63 years, deﬁned as those
who demonstrate poor glycemic control (HbA1c >7.5%) and
utilized >$600 of prescription medications the year prior to
study enrollment. A control group was identiﬁed who met the
same inclusion criteria, but who were not invited to the program
due to geographic constraints. Medical utilization costs were
analyzed beginning one year prior to study enrollment and
included inpatient, outpatient, emergency department, and pre-
scription costs. Health system charges, standardized to 2006
dollars, were used as a surrogate for costs. Intervention costs
were estimated from pharmacists’ wage rates. Medication adher-
ence was calculated as medication possession ratio (MPR) of
oral antidiabetic agents. HbA1c results were analyzed to deter-
mine glycemic control. RESULTS: Analysis of 46 subjects and
their matched controls one year after program implementation
showed positive trends, although none of the results were sta-
tistically signiﬁcant. The mean MPR for the intervention group
increased from 0.69 to 0.79, while there was no change from a
baseline of 0.64 for controls [p = 0.24]. Intervention patients
demonstrated a greater improvement (9.5% to 8.2%) in HbA1c
than controls (9.5% to 8.7%) [p = 0.15]. Although total
monthly health care costs increased in both the intervention
($1448 to $1756; difference = $308  $2016) and control
groups ($1089 to $1745; difference = $656  $2641) [p = 0.46],
the increase was lower in the intervention group. CONCLU-
SION: Patients in the intervention group trended toward better
medication adherence and a greater decline in HbA1c than con-
trols. We expect the trend of cost savings will continue and
strengthen in the future due to long-term beneﬁts associated with
sustained glycemic control.
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OBJECTIVE: Patient and provider “psychological insulin resis-
tance” can contribute to a delay in initiation of insulin therapy
in patients with type 2 diabetes (T2DM). Consequently, by the
time patients initiate insulin, complications may have already
developed. If patients initiate insulin but therapy is not intensi-
ﬁed to reach glycemic goal (HbA1c 7%), the ability to prevent
or delay complications may be compromised. The objective of
this study was to determine differences in the incidence of com-
plications of diabetes between patients with HbA1c <7% and
those with HbA1c 7%. METHODS: US health claims and
clinical laboratory data from 2003–2005 were used to identify
and stratify patients by mean HbA1c (controlled 7% vs. sub-
optimally controlled 7%) for analysis. Cohort was limited to
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